16-Thalidomide and dexamethasone oral SUPERSEDED | eviQ
They showed that single-agent thalidomide can induce a partial response in approximately 30% of patients with refractory myeloma. The combination of thalido-.
Thalidomide for Treating Metastatic Hepatocellular CarcinomaFurthermore, the TD regimen was administered to eight patients with primary refractory myeloma who were eligible for high-dose therapy with autologous stem cell. The Thalidomide StoryThalidomide (TD) was first developed as a safe sedative hypnotic in 1958 and was prescribed for pregnant women to prevent morning sickness. Immunomodulatory agents: Thalidomide - Knowledge HubRésumé. Le thalidomide, molécule tératogène retirée du marché en 1961, quatre ans après sa commercialisation est à l'origine de malformations graves ayant ...
Autres Cours:
